Cellcentric has signed an agreement with Takeda, a Japanese pharmaceutical company, that covers further validation of an epigenetic target.
Early evidence suggests that the protein plays an important role in cancer, and inhibitors to the target could offer ways to treat the disease.
Takeda also has an option to license the development programme.
The target is one of many that Cellcentric has identified for therapeutic product development.
The company's discovery engine is based on relationships with over 20 world authorities in epigenetics.
This enables the business to identify opportunities early, get access to the latest understanding of the area and accelerate drug discovery and development.
